Ceptaris Therapeutics (Malvern, PA) a clinical-stage specialty pharmaceutical company focused on the treatment of mycosis fungoides, a type of cutaneous t-cell lymphoma, closed a $14.4M Series D financing. Participants include Vivo Ventures, Palo Alto Investors, Burrill & Co. and Aperture Venture Partners.
Thanx for your patience as we catch-up.

NewBridge Pharmaceuticals (San Francisco, CA) a commercial-stage biopharmaceutical company focused on oncology, GI and metabolic disorders, closed a $12M Series B financing. Participants include Kuwait Life Sciences Company and Burrill & Co.

FerroKin Biosciences (San Carlos, CA) a preclinical-stage biopharmaceutical company focused on iron chelator for treatment of anemia, closed a $12M Series B financing. Participants include Clarus Ventures, Burrill & Co., Celegene, MP Healthcare Venture Management and Healthcap Ventures.

Endocyte (West Lafayette, IN) a clinical-stage biopharmaceutical focused on folate-receptor targeted receptors in ovarian, NSCLC and breast cancers and renal cell carcinoma, closed a $26M Series B financing. Participants include Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co. and Triathlon Medical Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

PrimeraDx (Mansfield, MA) a development-stage molecular diagnostics company focused on automated multiplexed assays of infectious disease testing in immune compromised patients undergoing solid organ and bone marrow transplant, closed a $20M Series C financing. Participants include CHL Medical Partners, Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Co. and Invus.